Abstract
Introduction
Citalopram overdose may produce bradycardia, QT prolongation, and torsades de pointes (TdP). A cardiotoxic metabolite may be responsible for the delayed onset of cardiotoxicity. Although some authorities recommend a minimum of 24 hours of observation following citalopram overdose, a recent analysis suggested that dysrhythmias rarely occur beyond 13 hours post-ingestion. We present a case of citalopram overdose with a substantially delayed onset of cardiac toxicity.
Case Report
A 36-year-old woman complained of shakiness, numbness in the arms, and palpitations that began approximately 32 hours after ingesting 50 (20-mg) tablets of citalopram. Her initial vital signs were: blood pressure, 84/44 mmHg; pulse, 102–150/minute; respirations, 17/min; temperature, 99.3° F (37.3° C). Her initial ECG showed sinus rhythm with a prolonged corrected QT interval (572 msec) with paroxysmal, self-limited runs of wide-complex tachycardia that appeared multifocal in nature. Approximately 20 minutes after presentation, she experienced self-terminating TdP, with transient hypotension and loss of consciousness. Her serum citalopram concentration (33 hours post-ingestion) was 477 ng/mL (therapeutic: 40–110 ng/mL); desmethylcitalopram concentration was 123.2 ng/mL (therapeutic: 14–40 ng/mL). She was treated with magnesium and lidocaine, and her corrected QT interval remained abnormal for 24 hours after presentation.
Discussion
Citalopram overdose can produce life-threatening cardiac toxicity with a clinical onset that may be delayed beyond a routine observation period of 6 hours. Once the QT interval is prolonged, it seems prudent to prolong the observation period.
Keywords: Citalopram, torsades de pointes, dysrhythmia, QTc
Full Text
The Full Text of this article is available as a PDF (332.3 KB).
References
- 1.Nemeroff CB. Overview of the safety of citalopram. Psychopharmacol Bull. 2003;37(1):96–121. [PubMed] [Google Scholar]
- 2.Hyttel J. Citalopram-pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry. 1982;6:277–295. doi: 10.1016/S0278-5846(82)80179-6. [DOI] [PubMed] [Google Scholar]
- 3.Kelly CA, Dhaun N, Laing WJ, Strachan FE, Good AM, Bateman DN. Comparative toxicity of citalopram and the newer antidepressants after overdose. J Toxicol/Clin Toxicol. 2004;42:67–71. doi: 10.1081/clt-120028747. [DOI] [PubMed] [Google Scholar]
- 4.Nelson LS, Erdman AR, Booze LL, et al. Selective serotonin reuptake inhibitor poisoning: An evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2007;45:315–332. doi: 10.1080/15563650701285289. [DOI] [PubMed] [Google Scholar]
- 5.Kobayashi T, Washiyama K, Ikeda K. Inhibition of G-protein-activated inwardly rectifying K+ channels by various antidepressant drugs. Neuropsychopharmacology. 2004;29:1841–1851. doi: 10.1038/sj.npp.1300484. [DOI] [PubMed] [Google Scholar]
- 6.Catalano G, Catalano MC, Epstein MA, Tsanbiras PE. QTc interval prolongation associated with citalopram overdose: A case report and literature review. Clin Neuropharmacol. 2001;24:158–162. doi: 10.1097/00002826-200105000-00007. [DOI] [PubMed] [Google Scholar]
- 7.Friberg LE, Isbister GK, Duffull SB. Pharmacokinetic-pharmacodynamic modeling of QT interval prolongation following citalopram overdoses. Br J Clin Pharmacol. 2006;61:177–190. doi: 10.1111/j.1365-2125.2005.02546.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Grundemar L, Wohlfart B, Lagerstedt C, Bengtsson F, Eklundh G. Symptoms and signs of severe citalopram overdose. Lancet. 1997;349:1602–1602. doi: 10.1016/S0140-6736(05)61630-3. [DOI] [PubMed] [Google Scholar]
- 9.Personne M, Persson H, Sjoberg G. Citalopram toxicity. Lancet. 1997;350:518–519. doi: 10.1016/S0140-6736(05)63109-1. [DOI] [PubMed] [Google Scholar]
- 10.Personne M, Sjoberg G, Persson H. Citalopram overdose—Review of cases treated in Swedish hospitals. J Toxicol/Clin Toxicol. 1997;35:237–240. doi: 10.3109/15563659709001206. [DOI] [PubMed] [Google Scholar]
- 11.Boeck V, Fredricson OK, Svendsen O. Studies on acute toxicity and drug levels of citalopram in the dog. Acta Pharmacol Toxicol. 1982;50:169–174. doi: 10.1111/j.1600-0773.1982.tb00959.x. [DOI] [PubMed] [Google Scholar]
- 12.Van Der Burgh M. Citalopram product monograph. Copenhagen, Denmark: H Lundbeck A/S; 1994. [Google Scholar]
- 13.Witchel HJ, Pabbathi VK, Hofmann G, Paul AA, Hancox JC. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS lett. 2002;512:59–66. doi: 10.1016/S0014-5793(01)03320-8. [DOI] [PubMed] [Google Scholar]
- 14.Isbister GK, Prior FH, Foy A. Citalopram-induced brady-cardia and presyncope. Ann Pharmacother. 2001;35:1552–1555. doi: 10.1345/aph.1A136. [DOI] [PubMed] [Google Scholar]
- 15.Engebretsen KM, Harris CR, Wood JE. Cardiotoxicity and late onset seizures with citalopram overdose. J Emerg Med. 2003;25:163–166. doi: 10.1016/S0736-4679(03)00164-1. [DOI] [PubMed] [Google Scholar]
- 16.Stork CM. Serotonin Reuptake Inhibitors and Atypical Antidepressants. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, Howland MA, Lewin NA, Nelson LS, editors. Goldfrank’s Toxicologic Emergencies. Eighth Edition. New York: McGraw Hill; 2006. pp. 1070–1082. [Google Scholar]
- 17.Isbister GK, Friberg LE, Duffull SB. Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose. Intensive Care Med. 2006;32:1060–1065. doi: 10.1007/s00134-006-0183-9. [DOI] [PubMed] [Google Scholar]